Asymmetric Dimethylarginine (ADMA)
ADMA is a naturally occurring amino acid that inhibits nitric oxide synthase, affecting vascular function and cardiovascular health.
ADMA is a biomarker for endothelial dysfunction and cardiovascular risk.
Key facts at a glance
- Units
- μmol/L
- Clinical utility
- prognostic
- Result kind
- quantitative
- FDA-cleared
- Immunodiagnostic ADMA, Roche ADMA
Asymmetric Dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), which plays a crucial role in regulating vascular tone and endothelial function. Elevated levels of ADMA are associated with impaired nitric oxide production, leading to endothelial dysfunction.
Research has shown that increased ADMA concentrations are linked to a higher risk of cardiovascular events, including hypertension, atherosclerosis, and heart failure. This makes ADMA a valuable prognostic marker for cardiovascular disease.
The normal reference range for ADMA is 0–0.55 μmol/L. Levels above this range may indicate an increased risk of cardiovascular complications and warrant further clinical evaluation.
Frequently asked questions
What is the role of ADMA in the body?
How can ADMA levels be reduced?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy